Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.45 |
| ▸ | RBP4 | P02753 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1739282 | 0.90 | EPHX2 (0.52) | EPHX2CYP2C9CYP2J2CYP2C19HMOX1 | |
| SCHEMBL14590499 | 0.85 | EPHX2 (0.53) | EPHX2CYP2C9CYP2J2CYP2C19RBP4 | |
| SCHEMBL14413608 | 0.85 | EPHX2 (0.53) | EPHX2CYP2C9CYP2J2CYP2C19HMOX1 | |
| SCHEMBL14408003 | 0.85 | EPHX2 (0.53) | EPHX2CYP2C9CYP2J2CYP2C19HMOX1 | |
| SCHEMBL1740304 | 0.83 | EPHX2 (0.44) | EPHX2CYP2C9CYP2J2CYP2C19HMOX1 | |
| SCHEMBL2775875 | 0.83 | HMOX1 (0.60) | EPHX2CYP2C9CYP2J2CYP2C19HMOX1 | |
| SCHEMBL15808601 | 0.83 | EPHX2 (0.51) | EPHX2CYP2C9CYP2J2CYP2C19HMOX1 | |
| SCHEMBL22174171 | 0.83 | EPHX2 (0.51) | EPHX2CYP2C9CYP2J2CYP2C19RBP4 | |
| SCHEMBL15808602 | 0.81 | EPHX2 (0.50) | EPHX2CYP2C9CYP2J2CYP2C19HMOX1 | |
| SCHEMBL5152829 | 0.81 | EPHX2 (0.63) | EPHX2RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225333-A1 | 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor | BRYANS JUSTIN S | 2007-09-27 | — | — | US | disclosed |
| EP-1742932-A1 | 3-HETEROCYCLYL-4-PHENYL-TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN V1A RECEPTOR | Pfizer Limited (GB) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005105779-A1 | 3-HETEROCYCLYL-4-PHENYL-TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN V1A RECEPTOR | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225333-A1 | 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor | AVPR2, RXFP3, AVPR1A | EPHX2 1357/4885CYP2C9 3062/4885CYP2J2 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.